luseogliflozin luseogliflozin luseogliflozin (trade name lusefi) is a pharmaceutical drug (an sglt2 inhibitor) used for the treatment of type 2 diabetes mellitus. it was approved for use in japan in 2014. in a meta-analysis involving data from 10 randomized controlled trials (1304 patients), dutta et. al. demonstrated the good glycaemic efficacy (mean glycated hemoglobin reduction of -0.76% and mean fasting glucose reduction of -26.69mg/dl) and safety of luseogliflozin 2.5mg/day as compared to placebo. additional benefits include significant reduction in systolic blood pressure (-4.19 mm hg), serum triglycerides (-12.60mg/dl), uric acid (-0.48mg/dl) and alanine aminotransferase (-4.11 iu/l) as compared to placebo, highlighting the beneficial impact on the different aspects of metabolic syndrome. luseogliflozinclinical datatrade nameslusefiother namests-071atc codea10bk07 (who) legal statuslegal status rx-only in japan identifierscas number898537-18-3pubchem cid11988953drugbankdb12214uniic596hwf74zcomptox dashboard (epa)dtxsid10237921 chemical and physical dataformulac23h30o6smolar mass434.55 g·mol−13d model (jsmol)interactive image smiles ccoc1=cc=c(c=c1)cc2=c(c=c(c(=c2)3((((s3)co)o)o)o)oc)c